Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01252186 · ClinicalTrials.gov registry record · Phase 2
A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women
A Phase 2 study, sponsored by Teva Women's Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 265
- Enrollment target
NCT01252186: Completed Phase 2 study, sponsored by Teva Women's Health.
NCT01252186 is a Phase 2 study that has completed, run by Teva Women's Health. The registered enrollment target is 265 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01252186, a Phase 2 study, has completed, sponsored by Teva Women's Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 265 participants
- Enrollment target
Study Summary
This study is being conducted to evaluate the impact of a 91-day extended cycle oral contraceptive compared to two 28-day oral contraceptive regimens on hemostatic parameters in healthy women.
Primary Outcome
Prothrombin fragment 1+2 is a coagulation factor, released when prothrombin is cleaved by activated factor X. Elevated plasma levels of prothrombin fragment 1+2 indicate high risk of thrombosis.
Interventions
- DRUG 91-day Levonorgestrel Oral Contraceptive
- DRUG 28-day Levonorgestrel Oral Contraceptive
- DRUG 28-day Desogestrel Oral Contraceptive
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 265 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
What the finished NCT01252186 record still lists
NCT01252186 is an interventional study that assigns participants to a tested intervention. The registered 265 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% higher).
The record links to 0 conditions, and to 3 interventions - of which 91-day Levonorgestrel Oral Contraceptive is the first listed.
NCT01252186 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01252186 about?
NCT01252186 is a clinical study titled "A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women". This study is being conducted to evaluate the impact of a 91-day extended cycle oral contraceptive compared to two 28-day oral contraceptive regimens on hemostatic parameters in healthy women.
What is the current status of trial NCT01252186?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 265 participants. The study started on 2010-11. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01252186?
The interventions under investigation include: 91-day Levonorgestrel Oral Contraceptive (DRUG), 28-day Levonorgestrel Oral Contraceptive (DRUG), 28-day Desogestrel Oral Contraceptive (DRUG).
Who is sponsoring clinical trial NCT01252186?
This trial is sponsored by Teva Women's Health, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01252186's enrollment target sits among peer trials
265 210th of 2000 higher than 1,791 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05443126 · 265 participants · Phase 1
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
- NCT05470491 · 265 participants · Phase 1
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
- NCT07301905 · 265 participants · NA
Culturally Targeted Health Communication and Receptivity to the Human Papillomavirus Vaccine Among Parents in Flint, MI
- NCT07470853 · 265 participants · Phase 1
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia